300511 雪榕生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.1002.336-49.501-11.405-16.833
总资产报酬率 ROA (%)0.5010.799-14.594-4.336-6.831
投入资产回报率 ROIC (%)0.6070.988-17.661-5.035-7.788

边际利润分析
销售毛利率 (%)17.24913.6233.6058.38410.704
营业利润率 (%)1.2502.146-28.385-7.422-16.166
息税前利润/营业总收入 (%)3.7054.820-24.115-4.215-12.923
净利润/营业总收入 (%)1.1871.933-28.505-7.498-16.985

收益指标分析
经营活动净收益/利润总额(%)555.07080.86533.50371.215-1.446
价值变动净收益/利润总额(%)6.9022.6830.1051.381-2.331
营业外收支净额/利润总额(%)-3.747-8.8230.4200.8901.426

偿债能力分析
流动比率 (X)0.3720.3450.2800.3630.919
速动比率 (X)0.1540.1330.1130.1530.577
资产负债率 (%)56.54657.97578.64068.87660.073
带息债务/全部投入资本 (%)40.80940.09666.34356.62647.234
股东权益/带息债务 (%)133.229139.76944.86271.595101.522
股东权益/负债合计 (%)81.99677.20930.96549.04271.264
利息保障倍数 (X)1.4821.692-5.493-1.287-3.717

营运能力分析
应收账款周转天数 (天)6.6426.8065.4004.3864.490
存货周转天数 (天)68.38273.07866.33567.87271.873